Swiss open to new US defence orders to tackle tariffs
GENEVA : Switzerland's defence minister Martin Pfister said Sunday he was 'open' to placing new arms orders with the US as a way to try to reduce Washington's whopping tariffs.
The Swiss government is seeking more talks with the US after a last-gasp mission to the US capital failed to stop a 39% tariff blow that businesses described as a 'horror scenario'.
'Military purchases are important for relations with the US,' Pfister told Switzerland's domestic Keystone-ATS news agency.
'However, we must first find a path for discussion with the Americans' to try to move relations forward overall, he said.
US President Donald Trump blindsided the Swiss when he announced that the wealthy Alpine nation would be hit by one of the highest tariffs among new duties on imports from dozens of economies that took effect on Thursday.
The tariff jeopardises entire sectors of the export-heavy Swiss economy, notably watchmaking and industrial machinery, but also chocolate and cheese.
Swiss businesses worry that competitors in other wealthy economies will have an edge, with the EU and Japan having negotiated a 15% tariff and Britain securing a rate of 10%.
Switzerland has argued that the US enjoys a significant services trade surplus and that most US industrial goods enter Switzerland tariff-free.
Pfister stressed that the government had decided not to call into question Switzerland's current contract to buy 36 new Lockheed Martin F-35A fighter jets.
'The issue of the fixed price remains to be resolved,' he added.
Switzerland and the US are quibbling over the final price of the F-35As bought to replace the ageing Swiss fleet.
The US Defense Security Cooperation Agency wants Switzerland to assume additional costs, but Bern says it is sticking to the agreed price of just over six billion Swiss francs (US$7.4 billion).
The F-35A combat aircraft – already used by the US Air Force and several European countries – was chosen in June 2021 instead of the Airbus Eurofighter, the F/A-18 Super Hornet by Boeing, and French firm Dassault's Rafale.
Switzerland's long-standing position has been one of well-armed military neutrality and the landlocked European country has mandatory conscription for men.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
15 minutes ago
- Malay Mail
Liverpool spend big in bid to cement Premier League supremacy
LIVERPOOL, Aug 14 — Fresh from storming to a record-equalling 19th English top-flight title, Liverpool have not held back in transforming Arne Slot's squad in pursuit of an era of Premier League dominance. On top of retaining veteran stars Virgil van Dijk and Mohamed Salah to new contracts, the Reds have splashed out £260 million (RM1.5 billion) and are reportedly far from finished in the transfer market. Two of the Bundesliga's most promising talents Florian Wirtz and Hugo Ekitike have arrived at Anfield to add extra creativity and goals. Jeremie Frimpong has also made the move from Germany with the daunting task of replacing Trent Alexander-Arnold at right-back, while Milos Kerkez joined from Bournemouth as the long-term successor to Andy Robertson at left-back. More defensive reinforcements are imminent with the club closing in on deals for Crystal Palace captain Marc Guehi and 18-year-old Italian centre-back Giovanni Leoni from Parma. But it is the potential addition of Newcastle striker Alexander Isak for a British transfer record fee in excess of £115 million that is the transfer saga of the English summer. Risky and rare strategy Liverpool were among the lowest Premier League spenders last year as Slot oversaw a steady transition from Jurgen Klopp in spectacular style. A huge investment this time round is also possible because the Reds are among the slickest movers in the market when it comes to sales. The departures of Luis Diaz, Darwin Nunez, Jarell Quansah, Caoimhin Kelleher, Alexander-Arnold and Tyler Morton have raised around £200 million. Liverpool's bold strategy of tearing up a title-winning team is a risky and rare experiment. Only once, Manchester City in 2019, have the Premier League champions been the biggest spending English club in the market since 2007. After years of battling against the financial power of Abu Dhabi-backed City, Liverpool are now flexing their muscles thanks to years of commercial growth and prudent ownership. 'It doesn't feel Liverpool-like to me,' said former defender Jamie Carragher at the thought of a new £69 million striker Ekitike playing second fiddle to Isak. After decades in the doldrums prior to Klopp's arrival, Liverpool are aiming to bring back glory days the club has not since the 1980s. The last time Liverpool won back-to-back titles was in 1984 and doing so this season would come with the added bonus of overtaking Manchester United as English football's top dogs. To do so, Slot has recognised the need to strike the right balance that still harnesses the best from his side's extra firepower. A pre-season trend of high-scoring encounters continued in losing the Community Shield to Crystal Palace on penalties after twice blowing the lead. 'Now we are better in creating and getting promising situations than we were, in my opinion, throughout the whole of last season,' said Slot. 'What made us really strong last season was we only won mostly by a margin of one goal and that had mostly to do with us keeping a clean sheet or as a maximum conceding one goal.' Liverpool also have extra motivation to defend their title as they try to honour a lost friend and team-mate in Diogo Jota. The Portuguese international was killed aged just 28 alongside his brother after a car accident in northern Spain last month. Tributes to Jota will continue throughout the season with 'Forever 20' — his shirt number, which the club have now retired — printed on Liverpool's jerseys. — AFP
New Straits Times
an hour ago
- New Straits Times
US pharma tariffs likely weeks away, sources say
WASHINGTON: The announcement by President Donald Trump's administration of the results of a probe into pharmaceutical imports and new sector-specific US tariffs likely remains weeks away, four official and industry sources said, later than initially promised as he focuses on other matters. Commerce Secretary Howard Lutnick had said in April when the review of whether reliance on foreign drug production threatens US national security was launched that he anticipated that it would conclude between mid-May and mid-June. Global pharmaceutical companies are bracing for the outcome of the investigation, which will usher in sector-specific tariffs that Trump has said could start small and eventually rise to 250 per cent. The Republican president said as recently as last week that his plan relies on phased-in tariffs, giving drugmakers time to increase manufacturing in the United States as he pushes to alter what he says are global trade distortions in many industries. One government official in Europe and a source with knowledge of the White House process, as well as two sources at European drug firms familiar with the process, told Reuters that the report and tariffs announcement was not imminent and likely weeks away. These sources spoke on condition of anonymity. A White House spokesperson, asked about media reporting indicating that the results of the probe could be several weeks away, cautioned that such reports were pure speculation unless confirmed by the White House. The spokesperson declined to give further details about the timing of the pharma probe or one involving semiconductors. The investigation is examining pharmaceutical imports ranging from finished prescription drugs to active pharmaceutical ingredients, called APIs, and other raw materials, with the results to be disclosed in a Commerce Department report. Lutnick said last month the tariff plan that will be based on the report would be completed by the end of July. Lutnick then said on July 29 it would be two more weeks. The investigation was launched under Section 232 of the Trade Expansion Act of 1962. While the investigation is ongoing, the pharmaceutical sector has been exempted from the sweeping tariffs imposed by the Trump administration. The United States has reached bilateral trade deals with the UK, Japan, South Korea and the European Union that promised more favorable terms for their pharma exports than those expected to be levied on the sector globally. A European government official said that an announcement before the end of August appears unlikely but cautioned that the timeline could shift depending on other developments. A source at a European drugmaker said the Trump administration is focused on the US-Russia summit in Alaska on Friday and therefore no announcement is expected this week. The source familiar with the White House process said that announcement is unlikely to come this week given other priorities. That source and one other source said that they expect the Trump administration to announce the results of its national security investigation into semiconductors first, followed by the pharma announcement, putting it a few weeks away. The Section 232 provision authorizes the president to adjust imports - including imposing tariffs - if a category of goods is being imported into the United States in quantities that "threaten or impair the national security." Medical goods historically have been spared from trade wars due to the potential harm to patient access, and drugmakers have said tariffs could undercut other health policy goals outlined by the Trump administration, including lowering drug prices. US tariffs on imported pharmaceutical products would mark the latest in a series of sectoral tariffs announced by the administration, following metals and cars, that some economists have predicted will drive up costs for American consumers.
New Straits Times
an hour ago
- New Straits Times
Bitcoin hits fresh record as Fed easing bets add to tailwinds
TOKYO: Bitcoin hit a record high on Thursday as increasing expectations for easier monetary policy from the Federal Reserve added to tailwinds from recently announced financial reforms. The world's largest crypto-asset by market capitalisation climbed as much as 0.9 per cent to US$124,002.49 in early Asia trading, surpassing its previous peak hit in July. On the day, the second largest crypto-token ether hit US$4,780.04, the highest level since late 2021. Bitcoin's rally is being powered by increasing certainty of Fed rate cuts, sustained institutional buying and moves by the Trump administration to ease investment in crypto assets, said IG market analyst Tony Sycamore. "Technically a sustained break above US$125k could propel BTC to US$150,000," he wrote in a note. Bitcoin has risen nearly 32 per cent so far in 2025 on the back of long-sought regulatory wins for the sector following President Donald Trump's return to the White House. Trump has called himself the "crypto president" and his family has made a series of forays into the sector over the past year. An executive order last week paved the way to allow crypto assets in 401(k) retirement accounts, highlighting an increasingly favorable regulatory environment in the United States. Crypto has scored multiple regulatory wins in the US over 2025, including the passage of stablecoin regulations and the US securities regulator's move to overhaul regulations in order to accommodate the asset class. Bitcoin's surge has also sparked a broader rally in the asset class over the past few months, shrugging off the tremors of Trump's wide-ranging tariff policies. According to data from CoinMarketCap, the crypto sector's overall market capitalisation has ballooned to over US$4.18 trillion, up from about US$2.5 trillion in November 2024, when Trump won the US presidential election. The latest push for crypto adoption in the United States came via an executive order on Thursday last week, which would ease access to the asset class in 401(k) retirement accounts. The executive order could also be a boost for asset managers such as BlackRock and Fidelity, which operate crypto exchange-traded funds (ETFs). Crypto's push into retirement savings can also be peppered with risks, as the asset class tends to experience much more volatility than stocks and bonds, which asset managers had typically relied on for such accounts.
